1. A pharmaceutical combination for use in glycemic control in patients with type 2 diabetes mellitus, said combination comprising (a) desProExendin-4 (1-39) -Lys-NHi / or a pharmaceutically acceptable salt thereof and (b) glitazone and / or its pharmaceutically acceptable salt. 2. The combination of claim 1, further comprising (c) metformin and / or a pharmaceutically acceptable salt thereof. The combination of claim 2, wherein metformin and / or a pharmaceutically acceptable salt thereof are prepared for oral administration. The pharmaceutical combination of claim 1 or 2, wherein the patient with type 2 diabetes is obese. The pharmaceutical combination of claim 1 or 2, wherein the patient with type 2 diabetes has a body mass index of at least 30 kg / m. The pharmaceutical combination of claim 1 or 2, wherein the patient with type 2 diabetes is an adult patient. The pharmaceutical combination of claim 1 or 2, wherein the patient with type 2 diabetes does not receive anti-diabetic treatment. A pharmaceutical combination according to claim 1 or 2, wherein in a patient with type 2 diabetes, type 2 diabetes was diagnosed at least 1 year or at least 2 years before starting therapy. The pharmaceutical combination of claim 1 or 2, wherein in a patient with type 2 diabetes, the HbA value is from about 7% to about 10% .10. The pharmaceutical combination of claim 1 or 2, wherein in a patient with type 2 diabetes, the fasting plasma glucose concentration is at least 8 mmol / L. The pharmaceutical combination according to claim 1 or 2, wherein in a patient with type 2 diabetes, the plasma glucose concentration at least 2 hours after a meal is at least 10 mmol / L, at least1. Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа, причем указанная комбинация содержит(a) desProExendin-4(1-39)-Lys-NHи/или его фармацевтически приемлемую соль и(b) глитазон и/или его фармацевтически приемлемую соль.2. Комбинация по п. 1, дополнит
